Vaccines

Sanofi to buy Dynavax for US$2.2 billion to add shingles vaccine

Some nine per cent have opted out of administering their kids with polio or MMR (measles, mumps, rubella) shots, a trend public health experts warn risks triggering a widespread return of potentially fatal illnesses that routine childhood vaccination had largely wiped out.

One in six US parents rejecting standard vaccine schedule: poll

Moderna shares dropped 7.4% in New York Friday. Pfizer shares fell 4%, while BioNTech’s US-traded shares sank 7.3%.

Drugmakers fall on report US to claim Covid shot killed kids

If fully enacted, Florida would become the first US state to abandon school vaccine requirements, long credited with wiping out once-common childhood scourges such as measles, mumps, rubella, polio and hepatitis B.

Florida to scrap all vaccine mandates, West Coast states push back

One logical fallacy used by tricksters is the false claim that since vaccines aren’t 100% safe and effective, they must be useless.
THE BROAD VIEW

Why bad arguments sound convincing

Seqirus will list on the Australian securities exchange by the end of this fiscal year.

Australian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce

Aside from flu shots, Ab&B is also developing vaccines for rabies, herpes and other respiratory diseases, with plans to commercialise them in China and beyond.

Chinese flu shot maker soars in Hong Kong trading debut

The deal is expected to close in the fourth quarter, and won’t have a significant impact on Sanofi’s financial guidance for the year.

Sanofi to buy Vicebio for up to US$1.6 billion in vaccine push

Moderna has been under pressure to find new sources of revenue as its Covid vaccine sales fall sharply and it spends heavily on its pipeline.

Trump team weighs pulling funds for Moderna bird flu vaccine

Merck can now integrate vaccine production within its own manufacturing network to supply global markets.

China’s WuXi Biologics to sell vaccine facility to Merck for US$500 million